AnteoTech Ltd (ASX: ADO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AnteoTech Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $67.22 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.49 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return -38.89%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AnteoTech Ltd (ASX: ADO)
    Latest News

    Man with rocket wings which have flames coming out of them.
    Small Cap Shares

    Guess which small cap ASX stock is rocketing 42% on Mercedes-Benz deal

    This small cap is ending the week with a very strong gain.

    Read more »

    Green arrow going up on stock market chart, symbolising a rising share price.
    Share Gainers

    Why Althea, AnteoTech, New Hope, and Omni Bridgeway shares are pushing higher

    These ASX shares are on form on Monday...

    Read more »

    Pilbara Minerals share price ASX lithium shares A stylised clean energy battery flexes its muscles, indicating a strong lift in share price for ASX energy companies
    Industrials Shares

    Anteotech share price surges 20% after passing first lithium battery hurdle

    AnteoTech shares are on fire on Monday morning...

    Read more »

    A young women pumps her fists in excitement after seeing some good news on her laptop.
    Share Gainers

    Why these 2 ASX All Ordinaries shares are surging more than 20% today

    Two ASX technology shares are leading the charge higher today.

    Read more »

    A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
    Healthcare Shares

    Why the AnteoTech share price is rocketing 33% today

    What did AnteoTech update the ASX with?

    Read more »

    Two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.
    Healthcare Shares

    Here's why the Anteotech (ASX:ADO) share price is leaping 6% today

    What news did this biotech company deliver today?

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Healthcare Shares

    The AnteoTech (ASX:ADO) share price RAT-tles down 8% following TGA update

    The TGA has asked for more clinical data, so further trials will now be conducted.

    Read more »

    A bright graphic showing neon green and red arrows in a downwards direction with a world map behind them in neon blue
    Share Fallers

    Why AnteoTech, ASX, CIMIC, and Temple & Webster shares are dropping

    These ASX shares are falling on Thursday...

    Read more »

    Woman holding a rapid antigen test.
    Healthcare Shares

    Rats! How have AnteoTech (ASX:ADO) shares already gained 30% in February?

    AnteoTech is riding on the back of RATs in February...

    Read more »

    A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
    Coronavirus News

    Why are ASX COVID test shares climbing today?

    COVID-19 tests are in focus again today.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    AnteoTech (ASX:AD) share price surges 15% as COVID-19 RAT race continues

    The scientific company's shares have bounced back after a horror start to the week.

    Read more »

    man grimaces next to falling stock graph
    Healthcare Shares

    Why did the AnteoTech (ASX:ADO) share price tumble 13% on Monday

    AnteoTech shares have suffered in the past week.

    Read more »

    Frequently Asked Questions

    No, AnteoTech does not pay dividends at this time.

    AnteoTech Ltd listed on the ASX on 7 April 2000.

    ADO ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AnteoTech Ltd

    AnteoTech Ltd (ASX: ADO) is a biotechnology company that uses its globally patented particle surface management technology to develop specialty products and services. The company's two key fields are end-user diagnostic products and battery technology.

    Its Life Sciences division is centred around AnteoBind, a product that connects biological and synthetic surfaces. The technology has various applications and also assists other diagnostic researchers in developing new products and medical devices.

    Meantime, the company's Energy division uses AnteoX binding technology to boost the performance of silicon-containing anodes delivering increased capacity, extended cycle life, and superior mechanical properties in lithium-ion batteries.

     

    ADO Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    08 Nov 2024 $0.03 $0.00 0.00% 634,190 $0.03 $0.03 $0.03
    07 Nov 2024 $0.03 $0.00 0.00% 448,423 $0.03 $0.03 $0.03
    06 Nov 2024 $0.03 $0.00 0.00% 1,130,108 $0.03 $0.03 $0.03
    05 Nov 2024 $0.03 $0.00 0.00% 309,551 $0.03 $0.03 $0.03
    04 Nov 2024 $0.03 $0.00 0.00% 541,698 $0.03 $0.03 $0.03
    01 Nov 2024 $0.03 $0.00 0.00% 731,630 $0.03 $0.03 $0.03
    31 Oct 2024 $0.03 $0.00 0.00% 1,322,874 $0.03 $0.03 $0.03
    30 Oct 2024 $0.03 $0.00 0.00% 2,816,051 $0.03 $0.03 $0.03
    29 Oct 2024 $0.03 $0.00 0.00% 4,806,660 $0.03 $0.03 $0.03
    28 Oct 2024 $0.03 $0.00 0.00% 1,990,220 $0.03 $0.03 $0.03
    25 Oct 2024 $0.03 $0.00 0.00% 1,135,671 $0.03 $0.03 $0.03
    24 Oct 2024 $0.03 $0.00 0.00% 1,247,278 $0.03 $0.03 $0.03
    23 Oct 2024 $0.03 $0.00 0.00% 495,519 $0.03 $0.03 $0.03
    22 Oct 2024 $0.03 $0.00 0.00% 3,804,374 $0.03 $0.03 $0.03
    21 Oct 2024 $0.03 $0.00 0.00% 7,543,910 $0.03 $0.03 $0.03
    18 Oct 2024 $0.03 $0.00 0.00% 44,196,716 $0.03 $0.04 $0.03
    15 Oct 2024 $0.03 $0.01 50.00% 14,207,918 $0.02 $0.03 $0.02
    14 Oct 2024 $0.02 $0.00 0.00% 604,565 $0.02 $0.02 $0.02
    11 Oct 2024 $0.02 $0.00 0.00% 195,936 $0.02 $0.02 $0.02
    10 Oct 2024 $0.02 $0.00 0.00% 1,187,823 $0.02 $0.02 $0.02

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    02 Oct 2024 David Radford Buy 754,007 $16,588
    On-market trade.
    13 Sep 2024 David Radford Issued 2,820,000 $62,040
    Conversion of securities.
    04 Sep 2024 David Radford Expiry 829,200 $19,071
    Options expired.
    31 May 2024 Ewen Crouch Buy 2,000,000 $50,000
    Placement.
    31 May 2024 Ewen Crouch Issued 1,000,000 $24,000
    Participation in share purchase plan.
    31 May 2024 Katherine Woodthorpe Buy 800,000 $20,000
    Placement.
    31 May 2024 Katherine Woodthorpe Issued 400,000 $9,600
    Participation in share purchase plan.
    31 May 2024 Geoffrey Cumming Buy 1,200,000 $30,000
    Placement.
    31 May 2024 Geoffrey Cumming Issued 600,000 $14,400
    Participation in share purchase plan.
    22 Dec 2023 Geoffrey Cumming Expiry 1,500,000 $51,000
    Options expired.
    14 Nov 2023 Katherine Woodthorpe Issued 1,500,000 $21,900
    Issue of options.
    14 Nov 2023 Ewen Crouch Issued 2,500,000 $36,500
    Issue of options.
    14 Nov 2023 Ewen Crouch Issued 468,750 $12,656
    Participation in share purchase plan.
    14 Nov 2023 Glenda McLoughlin Issued 468,750 $12,656
    Participation in share purchase plan.
    14 Nov 2023 Glenda McLoughlin Issued 1,500,000 $21,900
    Issue of options.
    14 Nov 2023 David Radford Issued 10,000,000 $146,000
    Issue of options.
    14 Nov 2023 David Radford Issued 468,750 $12,656
    Participation in share purchase plan.
    14 Nov 2023 Geoffrey Cumming Issued 468,750 $12,656
    Participation in share purchase plan.
    14 Nov 2023 Geoffrey Cumming Issued 1,500,000 $21,900
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Katherine Leslie Woodthorpe Non-Executive Director Sep 2021
    Dr Woodthorpe is a Chair and Non-Executive Director serving for over 20 years on the boards of a variety of organisations including listed entities, government boards and for-purpose organisations. She has a record in a range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. She is also a member of the Risk Committee.
    Dr Geoffrey James Cumming Non-Executive Director Apr 2009
    Dr Cumming has over 20 years of experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and on the Board. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss-making business to one achieving over 30% compound annual growth over a four-year period and the profitability levels in Roche's global organisation. He was also Managing Director and CEO of Biosceptre Ltd, an Australian-based biotechnology company commercialising a range of products in cancer diagnosis and treatment. He is member of the Risk Committee and Clinical Advisory Board.
    Ms Glenda McLoughlin Non-Executive Director Sep 2021
    Ms McLoughlin has commercial experience as a senior investment banker, commercial advisor and founder. She has over 20 years of experience on listed company boards. In her executive career she held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. She is also Chair of the Risk Committee.
    Mr Richard Shubrick Martin Non-Executive Director Sep 2005
    Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
    Mr David John Radford Chief Executive OfficerManaging Director Oct 2022
    Mr Radford has direct experience in coordinating international teams, executing business turnarounds, product development and product launches, and operational initiatives to drive material growth in revenue and profits. He has experience managing and communicating with multiple stakeholders from his experience across public capital markets, private companies and working directly with private equity investors. He is member of the Risk Committee.
    Mr Ewen Graham Wolseley Crouch Non-Executive ChairmanNon-Executive Director Apr 2022
    Mr Crouch was a Partner at Allens from 1998 to 2013 where his roles included Chairman of Partners, Co-Head Mergers and Acquisitions and Equity Capital Markets, Executive Partner - Asian Offices and Deputy Managing Partner, as well as 11 years of service on its board. He served as a Director of Mission Australia between 1995 and 2016, including 7 years as its Chairman. Ewen served as a Non-Executive Director of Westpac Banking Corporation from 2013 to 2019. He is also a member of the Risk Committee.
    Mr Andrew Cook Company Secretary Aug 2023
    -
    Katrina Byrne Chief Operating Officer
    -
    Andrew Cook Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Levenson Investments Pty Ltd 62,500,000 2.53%
    Marcolongo Nominees Pty Ltd 57,505,701 2.33%
    First Cape Management Pty Ltd 55,195,509 2.24%
    Addison Lake Quality Hire Pty Limited 38,844,879 1.57%
    BNP Paribas Noms Pty Ltd 35,212,229 1.43%
    Fossil Super Pty Ltd 30,100,000 1.22%
    Mr Peter Frederick Kemmis 27,090,676 1.10%
    Bond Street Custodians Limited 26,267,749 1.06%
    Mr Anthony William Olding & Mrs Caroline Anne Olding 24,617,142 1.00%
    Marcolongo Nominees Pty Ltd i 23,356,544 0.95%
    AWO & CAO Investments Pty Ltd 23,050,000 0.93%
    Computer Visions Pty Ltd 22,132,994 0.90%
    Mcrae Superannuation Pty Ltd 22,125,000 0.90%
    BNP Paribas Nominees Pty Ltd 21,915,497 0.89%
    Mrs Mary Curtis 19,617,450 0.79%
    Terry & Linden Deavin Super Pty Ltd 18,409,284 0.75%
    HSBC Custody Nominees (Australia) Limited 17,857,374 0.72%
    Mr Claus Kurt Dzalakowski 17,000,000 0.68%
    Mr Richard Shubrick Martin & Mrs Fiona Diana Martin 16,862,514 0.68%
    Mrs Elaine Janice Salisbury 15,400,000 0.62%

    Profile

    since

    Note